Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;51(3):238-45.
doi: 10.1016/j.jemermed.2016.05.005. Epub 2016 Jun 27.

The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran

Zachary D W Dezman  1 , Angela C Comer  2 , Gordon S Smith  2 , Mayur Narayan  3 , John R Hess  4 , Jon Mark Hirshon  1
Affiliations

The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran

Zachary D W Dezman et al. J Emerg Med. 2016 Sep.

Abstract

Background: Dabigatran, a direct thrombin inhibitor, has been shown to be more effective than warfarin in the prevention of stroke in patients with atrial fibrillation. Until recently, it lacked a reversal agent, and its contribution to the risk of transfusion in injured patients is unknown.

Objective: We sought to determine whether patients who sustain traumatic injuries while taking dabigatran receive more blood transfusions than matched patients taking warfarin, aspirin, clopidogrel, or controls.

Methods: This retrospective, single-center cohort consisted of injured patients who were taking dabigatran before admission to a major trauma center (January 2010-December 2013) who were compared with cohorts of patients taking warfarin, clopidogrel, or aspirin and a control group. The outcome was bleeding risk as measured by the use of blood products, with mortality as a secondary outcome. Outcomes were controlled for by age, sex, injury severity, and blunt mechanism.

Results: Thirty-eight patients were taking dabigatran. Compared with the general trauma population, patients taking dabigatran were more likely to be male, older, and to have higher injury severity. Patients taking dabigatran received transfusions (odds ratio [OR] 1.31 [95% confidence interval {CI} 0.56-3.04]), packed red blood cells (OR 1.43 [95% CI 0.54-3.77]), frozen plasma (OR 1.20 [95% CI 0.42-3.49]), and platelets (OR 2.01 [95% CI 0.63-6.37]) as often as matched controls. The mortality rate among patients on dabigatran was 12.5% (OR 1.51 [95% CI 0.39-5.89]) compared with 9.1% in matched controls. None of these results was statistically significant.

Conclusions: In this small study, injured patients taking dabigatran were transfused as often and had similar in-hospital mortality as matched controls who were not taking anticoagulants.

Keywords: dabigatran; epidemiology; hematology; mortality; transfusion; trauma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram showing the excluded groups and the number of subjects in each cohort. ISS = Injury Severity Score.
See this image and copyright information in PMC

Comment in

References

    1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest. 2008;133(6 suppl):381S–453. - PubMed
    1. Goldhaber SZ, Fanikos J. Prevention of deep vein thrombosis and pulmonary embolism. Circulation. 2004;110:e445–7. - PubMed
    1. Kushner FG, Hand M, Smith SC, Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guildine and 2007 Focused Update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–306. - PubMed
    1. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:1144–50. - PubMed
    1. Budnitz DS, Pollock DA, Weidenbach KN, et al. National Surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296:1858–66. - PubMed

MeSH terms